clopidogrel + aspirin OR prasugrel + aspirin — Competitive Intelligence Brief

clopidogrel + aspirin OR prasugrel + aspirin (clopidogrel + aspirin OR prasugrel + aspirin) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dual antiplatelet therapy (DAPT). Area: Cardiovascular.

marketed Dual antiplatelet therapy (DAPT) P2Y12 receptor (clopidogrel/prasugrel) and cyclooxygenase (aspirin) Cardiovascular Small molecule

Target snapshot

clopidogrel + aspirin OR prasugrel + aspirin (clopidogrel + aspirin OR prasugrel + aspirin) — Abbott Medical Devices. This dual antiplatelet therapy combines two P2Y12 inhibitors (clopidogrel or prasugrel) with aspirin to prevent blood clots by blocking platelet aggregation through different pathways.

Comparator set (2 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
clopidogrel + aspirin OR prasugrel + aspirin TARGET	clopidogrel + aspirin OR prasugrel + aspirin	Abbott Medical Devices	marketed	Dual antiplatelet therapy (DAPT)	P2Y12 receptor (clopidogrel/prasugrel) and cyclooxygenase (aspirin)
Standard-DAPT of Ticagrelor plus aspirin	Standard-DAPT of Ticagrelor plus aspirin	Second Affiliated Hospital, School of Medicine, Zhejiang University	marketed	Dual antiplatelet therapy (DAPT); P2Y12 inhibitor + cyclooxygenase inhibitor	P2Y12 receptor (ticagrelor); cyclooxygenase-1 (aspirin)
Early Dual Antiplatelet Therapy	Early Dual Antiplatelet Therapy	Beijing Tiantan Hospital	phase 3	Dual antiplatelet therapy (DAPT)	Cyclooxygenase (COX) and P2Y12 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dual antiplatelet therapy (DAPT) class)

1. Abbott Medical Devices · 1 drug in this class
2. Beijing Tiantan Hospital · 1 drug in this class